Community-based participatory research (CBPR) is challenging to research ethics committees (RECs). We reviewed the REC preparedness when reviewing CBPR projects. We searched the MEDLINE database and included qualitative studies of CBPR researchers or REC members about their experiences with RECs. The search yielded 107 studies, of which 10 met our criteria. Barriers were that the community is not prepared to conduct research, the reluctance of RECs to work outside the university, the difficulty RECs have understanding CBPR, and that REC forms evaluate individual rather than community risk. Facilitators were having a CBPR expert as an REC member and educating RECs. Therefore, RECs are not prepared to evaluate CBPR projects leading to unnecessary delays in the approval process.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1556264615615008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethics Committees' Practices in Healthcare, Banking and Research: Key Requirements for Their Functionality.
J Eval Clin Pract
February 2025
Institute of the History of Medicine and Ethics in Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Rationale: To meet concerns about ethical and unethical behavior in their work environments and workplaces, organizations began establishing ethics programs that contain ethics committees (ECs). There is now a tradition and diverse use of ECs for ethical decision-making in many different organizational settings. In addition, ECs have been subject to many publications in books and articles in the scientific literature.
View Article and Find Full Text PDFHow do we measure the costs, benefits, and harms of sharing data from biomedical studies? A protocol for a scoping review.
Open Res Eur
January 2025
Heidelberger Institut für Global Health, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, 69120, Germany.
Introduction: The benefits of sharing participant-level data, including clinical or epidemiological data, genomic data, high-dimensional imaging data, or human-derived samples, from biomedical studies have been widely touted and may be taken for granted. As investments in data sharing and reuse efforts continue to grow, understanding the cost and positive and negative effects of data sharing for research participants, the general public, individual researchers, research and development, clinical practice, and public health is of growing importance. In this scoping review, we will identify and summarize existing evidence on the positive and negative impacts and costs of data sharing and how they are measured.
View Article and Find Full Text PDFReadability of informed consent documents and its impact on consent refusal rate.
Perspect Clin Res
August 2024
Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Introduction: Informed consent documents (ICDs) are integral to a research project and must provide all required information to the participant. We undertook a 6-year retrospective cross-sectional analysis of ICDs to assess the same.
Methods: We accessed 300 ICDs from studies submitted to institutional ethics committee.
Modeling the determinants of cigarette consumption in Iranian households with children under 5 years of age using the Income and Expenditure Survey 2021.
Arch Public Health
January 2025
Department of Biostatistics & Epidemiology, School of Public Health, Infectious Ophthalmologic Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background: Cigarette smoking remains a significant public health concern, with detrimental effects on both smokers and those exposed to secondhand smoke. This study investigates the factors influencing smoking behaviors in Iranian households, focusing on households with children under five years old.
Methods: We conducted a cross-sectional analysis of 8751 Iranian households using data from the Iranian Household Income and Expenditure Survey (HIES) collected by the Statistical Center of Iran (SCI) in 2021.
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
BMC Cancer
January 2025
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!